Sign in
4

Changes in Ownership

Axsome Therapeutics, Inc. Filed Acc 0000950170-25-021716

Chief Financial Officer sold 15,000 shares at an average $130.10 ($1,951,530)

  • Chief Financial Officer acquired 15,000 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Table I: Non-derivative

Insider Date Transaction Shares Price Value Owned after D/I
Pizzie Nick Chief Financial Officer 2025-02-13 Option exercise 10b5-1 +12,000 $3.50 $42,000 54,187 D: show line 1 in the form
Pizzie Nick Chief Financial Officer 2025-02-13 Sale 10b5-1 −12,000 $129.86 $1,558,320 42,187 D: show line 2 in the form
Pizzie Nick Chief Financial Officer 2025-02-14 Option exercise 10b5-1 +3,000 $3.50 $10,500 45,187 D: show line 3 in the form
Pizzie Nick Chief Financial Officer 2025-02-14 Sale 10b5-1 −3,000 $131.07 $393,210 42,187 D: show line 4 in the form
Open-market sales · 15,000 sh · avg $130.10 · $1,951,530

Table II: Derivative

Insider Date Transaction Shares Price Value Owned after D/I
Pizzie Nick Chief Financial Officer 2025-02-13 Option exercise · Stock Option (Right to Buy) 10b5-1 −12,000 $3.50 $42,000 0 D: show line 5 in the form
Pizzie Nick Chief Financial Officer 2025-02-14 Option exercise · Stock Option (Right to Buy) 10b5-1 −3,000 $3.50 $10,500 0 D: show line 6 in the form
Loading xslF345X05/ownership.xml…